A new inter partes review, IPR2026-00391, was filed on June 5, 2026, at the Patent Trial and Appeal Board naming Teladoc Health, Inc. in the proceeding. The filing places another spotlight on the digital health and telemedicine patent landscape, where platform functionality, remote care workflows, and software-driven healthcare delivery continue to generate high-stakes validity disputes.

At this early stage, the PTAB docket identifies the proceeding by title but may not yet reflect the full set of publicly available petition details practitioners typically watch for, including the specific patent number, the complete alignment of petitioner and patent owner, and the precise prior-art combinations asserted in the challenge.

The SEC has settled insider-trading charges against Weizheng Zeng in an administrative proceeding arising from the acquisition of Chimerix, Inc. by Jazz Pharmaceuticals plc. In SEC v. Weizheng Zeng (File No. 3-22627), the agency alleged that Zeng traded Chimerix stock while participating in due diligence work connected to Jazz’s acquisition of the company, before the deal was publicly announced on March 5, 2025.

According to the SEC, those trades generated roughly $69,011 in illicit profits.